KalVista Pharmaceuticals, Ltd.

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Phase 32

By Therapeutic Area

top 1

Rare Disease

133%

R&D Momentum

32/100

Pipeline Velocity

6/100

Trial Completion Rate

89/100

Pipeline Concentration

56/100

Pipeline Freshness

74/100

Strategic Signals

↗Active in Rare Disease but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 21, 2026

Approved for marketing

Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat

Sep 18, 2026

Recruiting

A Phase 4, Open-Label Trial to Evaluate the Safety and Effectiveness of Sebetralstat When Used as Preprocedural Short-term Prophylaxis in Patients With Hereditary Angioedema

Earlier

Aug 6, 2026TrialOpen-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With Hereditary Angioedema Type I or II

Jul 24, 2026TrialOn Demand Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With Hereditary Angioedema (HAE) With Sebetralstat

Jul 3, 2025FDAEkterly — EKTERLY

Oct 24, 2022TrialAn Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Oct 24, 2022TrialPK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

Feb 22, 2022TrialA Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

4 more events

Sep 27, 2021TrialA Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II

May 19, 2020TrialPhase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Jul 2, 2019TrialA Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II

Feb 12, 2019TrialA Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Ekterly5 patentsNov 26, 2035 Ekterly2 patentsJun 23, 2037 EkterlyJan 26, 2039

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

KVD900Phase 3

Unknown / Other

Adolescent

Drug: KVD900Phase 3

KVD900Phase 3

Regulatory

Regulatory Timeline

20251 event

FDAJul 3

Ekterly — EKTERLY

Application NDA219301 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)